-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Roche’s Genentech announced the latest 2-year data from three Phase 3 clinical trials of two ophthalmic therapies, Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection)
.
Susvimo, approved last October for the treatment of wet age-related macular degeneration (AMD) patients, is the first FDA-approved treatment for wet AMD that requires only two treatments a year
These long-term results further support the ability of these two therapies to treat patients with longer treatment intervals and less frequent eye injections, while still achieving and maintaining vision improvements similar to current standard of care
.
Wet AMD is the leading cause of vision loss in people over the age of 60
.
The current standard of care is ocular injections of anti-vascular endothelial growth factor (VEGF) antibodies, but responses vary from patient to patient, and some may require more than 10 injections per year to achieve significant results
▲Introduction to Susvimo (Image source: Roche’s official website)
DME is caused by vascular damage and leakage in the central region of the retina, causing macular edema, common in older diabetic patients, and can lead to blindness
.
As a bispecific antibody, Vabysmo simultaneously targets and blocks two key pathogenic pathways, angiopoietin-2 (Ang-2) and VEGF-A, both of which can destabilize blood vessels and make Blood vessels leak, increasing inflammation
▲Schematic diagram of the structure of Faricimab (Image source: Reference [2])
Results from two Phase 3 clinical trials showed that at least 60% of patients eligible for the extended dosing interval of Vabysmo could receive treatment every 4 months for two years and was comparable to the current standard of care with dosing every 2 months.
The visual benefit met the non-inferiority criteria, which was only about 50% higher than at 1 year of treatment
.
Combining the two trials, nearly 80% of patients eligible to extend the dosing interval of Vabysmo were able to extend the treatment interval beyond 3 months by the end of Year 2
Long-term results from another phase 3 trial evaluating Susvimo showed that 95% of subjects were able to maintain 6-month dosing intervals at 2 years of treatment with no additional treatment, compared with monthly ranibizumab.
References:
[1] New Two-Year Data for Genentech's Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss.
[2] Sharma et al.
(Original abridged)
